Navigation Links
Dennis R. Hill, MD to be a Panelist at the Third Annual Prostate Cancer Symposium Focusing on the Changing Paradigm of Prostate Cancer
Date:8/17/2013

Oakland, CA (PRWEB) August 17, 2013

Dennis R. Hill, MD has confirmed today that he will be a panelist at the Third Annual Prostate Cancer Symposium titled “The Changing Paradigm of Prostate Cancer: Selective screening, Personalized Treatment and Survivorship in a Period of Rapid Progress.” The event will be Tuesday, September 17 from 5:30 to 8:30pm and is sponsored by the Alta Bates Summit Health Education Center. At this year’s symposium an expert panel of physicians and professionals address the newest treatment options for prostate cancer, and how to pro-actively address quality of life and health issues during and after treatment. Discussions will cover screening, watchful waiting, treatment technology, nutrition, physical fitness as well as possible side effects like incontinence and urinary issues.

Dr. Hill’s presentation will be on High Dose Rate Brachytherapy for prostate cancer treatment vs Surveillance. Dr. Hill comments, “There is a changing paradigm in prostate cancer on several fronts, including screening, diagnosis and treatment. It can be confusing. Hopefully, this panel will not only bring the latest information out, but also some common sense on how to approach this important cancer.” The other physician panelists will present “Rational Approach to Screening and Treatment Decisions in the Era of Genetic Assessment” and “The Urologist’s Perspective on Surveillance vs Treatment” and “The March towards Controlling Recurrent and Aggressive Prostate Cancer.” There will also be panelist presentations on enhancing survivorship quality by a nutritionist and a physical therapist.

Following the presentations there will be a question and answer session with the panelists. The event is open to the public and will be held at Alta Bates Summit Health Education Center, 400 Hawthorne Avenue, Oakland, CA 94609. Reservations are required. To reserve a seat call (510) 204-5804 or send an email to slaveni(at)sutterhealth(dot)org.

About Dennis R. Hill MD

Dr. Hill has been doing High Dose Rate Brachytherapy for prostate cancer treatment exclusively since 2004 and has published scholarly articles on the subject. His office is located at: Dennis R. Hill MD 3012 Summit Street Suite 2675 Oakland, CA 94609 510-869-8875 drh(at)dennisrhillmd(dot)com and his website is hdrprostatebrachytherapy.com, which includes a quiz to determine if a patient is a candidate for HDR Prostate Brachytherapy.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11027402.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Paratek Announces Appointments of Dennis Molnar as Chief Executive Officer and Director and of Dr. Evan Loh as Chief Medical Officer and Chairman of the Board of Directors
2. Althea Technologies Appoints Dr. Dennis Fenton As Chairman Of Its Scientific Advisory Board
3. Dennis R. Hill MD HDR Prostate Brachytherapy Specialist Compares Prostate Cancer Treatment Options: Not All Low Dose Rate Brachytherapy Isotopes Are the Same
4. Dennis R. Hill, MD to Speak at the American Cancer Society Man-to-Man Support Group to Discuss HDR Brachytherapy for Prostate Cancer Treatment
5. Oramed CEO to be Panelist at BIO International Convention Breakout Session on Israel Becoming Biotech Leader
6. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
7. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
8. WuXi PharmaTech Announces Third-Quarter 2011 Results
9. Interleukin Genetics Reports Third Quarter 2011 Financial Results
10. Spherix Announces Third Quarter Financial Results
11. Nile Therapeutics Reports 2011 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... and PLYMOUTH, Minn., July 20, 2017 /PRNewswire/ ... , a personalized genetic evaluations company, today announced ... their partnership investigating a genetic mutation implicated in ... extend the partnership for a second case involving ... year, the KCNQ2 Cure Alliance and Pairnomix entered ...
(Date:7/18/2017)... ... July 18, 2017 , ... ... that Merck, a leading science and technology company, has implemented Genedata Biologics ... the therapeutic areas of Oncology, Immunology, and Neurodegenerative Diseases. , The need to ...
(Date:7/17/2017)... ... July 17, 2017 , ... Whitehouse Laboratories is excited ... encompass the full series of ISO 80369 standard test procedures. The ISO 80369 ... and drug delivery systems. With this recent expansion, Whitehouse Labs becomes one of ...
(Date:7/17/2017)... (PRWEB) , ... July 17, 2017 , ... ... Weihong Hsing, Ph.D. , recently participated in the BiG (Biomedical Innovation Group) ... was dominated by discussions of CAR-T (chimeric antigen receptor T-cell) therapy, a rapidly ...
Breaking Biology Technology:
(Date:3/28/2017)... 2017 The report "Video Surveillance ... Servers, Storage Devices), Software (Video Analytics, VMS), and Service ... Forecast to 2022", published by MarketsandMarkets, the market was ... projected to reach USD 75.64 Billion by 2022, at ... base year considered for the study is 2016 and ...
(Date:3/24/2017)... 2017 Research and Markets has announced the ... & Trends - Industry Forecast to 2025" report to their ... The Global ... CAGR of around 15.1% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
(Date:3/22/2017)... March 21, 2017   Neurotechnology , a ... technologies, today announced the release of the ... provides improved facial recognition using up to 10 ... single computer. The new version uses deep neural-network-based ... and it utilizes a Graphing Processing Unit (GPU) ...
Breaking Biology News(10 mins):